Dabigatran

General Information

Dabigatran Impurities and Dabigatran

Daicel Pharma synthesizes Dabigatran impurities of exceptional quality, such as (4-carbamoylphenyl)glycine, 2,2′-((4-cyanophenyl)azanediyl)diacetic acid, 4-[2-(Methylamino)-5-nitro-anilino]-4-oxo-butanoic acid impurity, and N-Nitroso Dabigatran etexilate. These impurities are crucial to assess the purity, reliability, and safety of an active pharmaceutical ingredient, Dabigatran. Besides, Daicel Pharma provides custom synthesis of Dabigatran impurities to meet clients’ demands for delivery worldwide.

Dabigatran [CAS: 211914-51-1], the active metabolite of Dabigatran etexilate, is a direct thrombin inhibitor that acts as an anticoagulant. It prevents stroke and systemic embolism. Dabigatran provides effective prevention against stroke and venous embolism in patients with chronic atrial fibrillation.

Dabigatran: Use and Commercial Availability  

Dabigatran is a potent small molecule that exerts its anticoagulant effects by directly binding to and inhibiting thrombin through ionic interactions at its active site. It effectively inhibits both free and clot-bound forms of thrombin rapidly and reversibly. Dabigatran etexilate, the prodrug form, undergoes first-pass metabolism to convert into the active derivative, Dabigatran, which has a relatively short half-life of approximately 40 minutes. The drug is available under the brand name Pradaxa.

Dabigatran Structure and Mechanism of Action

The chemical name of Dabigatran is N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-alanine. Its chemical formula is C₂₅H₂₅N₇O₃, and its molecular weight is approximately 471.5 g/mol.

Dabigatran and its acyl glucuronides competitively inhibit thrombin. It inhibits the formation of free and clot-bound thrombin.

Dabigatran Impurities and Synthesis

During the productio¹, storage, or degradation of Dabigatran, impurities may arise. These impurities form from various sources and may impact the quality and safety of the drug. Rigorous analysis using advanced techniques such as HPLC, LC, and MS is employed to identify and quantify these impurities. It is essential to implement stringent control measures to limit impurity levels and ensure the efficacy and safety of Dabigatran. Compliance with regulatory guidelines and continuous monitoring is necessary to maintain the purity and quality of the drug.

Daicel Pharma offers a Certificate of Analysis (CoA) for Dabigatran impurity standards, such as (4-carbamoyl phenyl)glycine, 2,2′-((4-cyanophenyl)azanediyl)diacetic acid, 4-[2-(Methylamino)-5-nitro-anilino]-4-oxo-butanoic acid impurity, and N-Nitroso Dabigatran etexilate, generated from an analytical facility compliant with cGMP standards. The CoA includes a comprehensive characterization report comprising data from techniques like 1H NMR, 13C NMR, IR, MASS², and HPLC purity. Furthermore, on request, we give additional data like 13C-DEPT and CHN. Daicel Pharma can synthesize unknown Dabigatran impurities or degradation products. A complete characterization report accompanies every delivery.